By admin 
At-home diagnostics startup Inito has raised $29 million in a Series B round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. The company’s total equity funding now stands at $45 million. It previously raised $6 million in a Series A round led by Fireside Ventures in November 2023. The new capital will support Inito’s move beyond fertility testing into broader hormone and health diagnostics built on AI-enabled antibody engineering.
Inito entered the market in 2021 with an at-home fertility device that measures four hormone markers and interprets results using proprietary models. According to the company, the product has processed more than 30 million data points globally. After reaching scale in fertility monitoring, the company is developing tests for additional biomarkers across women’s and general health.
Inito aims to create a stable, consistent foundation for at-home diagnostic tests that historically required clinical infrastructure. The brand is building products for testosterone, thyroid, vitamins and other analytes, targeting a wider health-monitoring use case. Inito has teams across Bengaluru, Dubai and London and holds more than 20 patents linked to its testing platform.
About Inito
Inito is a health-tech company from India that has been founded by Aayush Rai & Varun AV. Inito has been known for its at-home fertility monitor that uses AI-designed antibodies and smartphone integration to measure hormones (LH, FSH, Estrogen, PdG) for tracking ovulation and pregnancy chances, aiming to build a broader at-home diagnostics platform for various health concerns, recently raising significant funding for global expansion.